Intravenous γ-globulin inhibits binding of anti-GM1 to its target antigen

Annals of Neurology

Volumn 39, Issue 1, 1996, Pages 136-139

  Malik, Ummekalsoom ^a,c   Oleksowicz, Leslie ^a   Latov, Norman ^b   Cardo, Lisa J ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b New York Presbyterian Columbia University Medical Center   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M ANTIBODY;

ANTIGEN BINDING; ARTICLE; CASE REPORT; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MOTOR NEUROPATHY; PRIORITY JOURNAL; SERUM;

DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; G(M1) GANGLIOSIDE; GAMMA-GLOBULINS; HUMANS; IMMUNOGLOBULIN M; IMMUNOGLOBULINS, INTRAVENOUS; MOTOR NEURON DISEASE; PROTEIN BINDING;

EID: 0030070677     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410390121     Document Type: Article

References (14)

1. 1 antibody titers. Neurology 1994;44:1278-1282
2. 1 antibodies, and multifocal motor conduction block. Ann Neurol 1990;28:373-377
3. Nobile-Orazio E, Meucci W, Barbieri S, et al. High dose intravenous immunoglobulin therapy in multifocal motor neuropathy. Neurology 1993;43:537-543
4. Dalakas MC, Stin DP, Otero C, et al. Effect of high-dose intravenous immunoglobulin on amyotropic lateral sclerosis and multifocal motor neuropathy. Arch Neurol 1994;51:861-864
5. 1 antibodies: a double-blind, placebo-controlled study. Neurology 1994;44:429-432
6. Berchtold P, Dale GL, Tani P, McMillian R. Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by antiidioptypic antibodies in intravenous gammaglobulin. Blood 1989;74:2414-2417
7. Sultan Y, Kazatchkine MD, Nydegger U, et al. Intravenous immunoglobulin in the treatment of spontaneously acquired factor VIII:C Inhibitors. Am J Med 1991;91(suppl 5A):35S-39S
8. Thomas FP, Lee AM, Romas SN, Latov N. Monoclonal IgMs with anti-Gal(β1-3) GalNac activity in lower motor neuron disease; identification of glycoprotein antigens in neural tissue and cross-reactivity with serum immunoglobulins J Neuroimmunol 1989;23:167-174
9. Turner MW, Bennich HH, Narvig JB. Pepsin digestion of human G-myeloma proteins of different subclasses. The characteristic features of pepsin cleavage as a function of time. Clin Exp Immunol 1970;7:603-625
10. Noya FJ, Rench MA, Courtney JT, et al. Pharmacokinetics of intravenous immunoglobulin in very low birth weight neonates Pediatr Infect Dis J 1989;8:759-763
11. Latov N. Antibodies to glycoconjugates in neurologic disease. Clin Aspects Autoimmun 1990;4:18-29
12. Rossi F, Dietrich G, Kazatchkine MD. Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses. Immunol Rev 1989;110:135-149
13. Tankersiey DL. Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune diseases. Immunol Rev 1994;139.159-172
14. Axford JS, Sumar N, Alavi A, et al. Changes in normal glycosylation mechanisms in autoimmune rheumatic disease. J Clin Invest 1992;89:1021-1031